D
Deciphex
Transforming Pathology using Tailored Workflows and Artificial Intelligence
About Deciphex
Deciphex is building a global network of AI empowered pathologists, ensuring accessible, innovative pathology services that improve patient outcomes.
The pathology industry is beset with increasing caseload and diagnostic complexity, against a globally declining number of pathologists to service the workload.
We believe that digital pathology combined with computer aided diagnostic tools will help make pathologists work more efficiently in the future, and offers a solution to the pending crisis in supply/demand in pathology services.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2017
- Headquarters
- Dublin, Ireland
- Employees
- 186
- Open positions
- 8
- Dealroom signal
- 77.6/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Veterinary, Biotechnology, Medical Research, Pathology, Core AI, AI for medical imaging, AI Drug Discovery
- Technology
- Artificial Intelligence, Deep Tech, Machine Learning
- Business model
- SaaS
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES COther financing | Oct 2025 | $17M | $66M | Undisclosed | ↗ |
| SERIES COther financing | Jan 2025 | $32M | $129M | Seroba Life Sciences · NextSteps Capital · Molten Ventures · Act Venture Capital | ↗ |
Financials
Revenue, earnings and other financial measures where available. Years marked “E” are estimates.
Growth signals
Latest recorded traffic for Deciphex is 4.8K monthly website visits, up 71.4% over the last three months. Deciphex's team grew 3.9% over the past year.
Open positions
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed2 investors entered at this stage
- HIHorizon 2020 FTI (Fast Track to Innovation)
European Innovation Council
Series A10 investors entered at this stage
Act Venture Capital
Irrus Investments
Enterprise Ireland
GI Partners
Inova Personalized Health Accelerator
NextSteps Capital
GI Partners of Illinois
Novartis
Charles River Laboratories International- HMHBAN Medtech
Series B and later3 investors entered at this stage
Seroba Life Sciences
Claret Capital Partners
Molten Ventures
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Deciphex on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Deciphex’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.







